9G4-targeted bispecific T cell engagers and CAR-T cells
We developed IGHV4-34-targeted chimeric TCR-T cells, CAR-T cells, and bispecific T cell engagers, precision immunotherapies for the selective elimination of 9G4 idiotope B cells in lupus, cold agglutinin disease, and lymphoma.